P009 to Investigate the Prognostic Factors and the Significance of TKI in Advanced NSCLC With Wild-Type EGFR

Journal of Thoracic Oncology - United States
doi 10.1016/j.jtho.2018.10.033
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Comparison of EGFR-TKI and Chemotherapy in the First-Line Treatment of Advanced EGFR Mutation-Positive NSCLC

Neoplasma
Cancer Research
2013English

Resistance to EGFR-TKI Can Be Mediated Through Multiple Signaling Pathways Converging Upon Cap-Dependent Translation in EGFR-Wild Type NSCLC

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2013English

P1.01-60 Preventing and Treating Brain Metastases With Three First-Line EGFR-TKI in Patients With EGFR Mutation Advanced NSCLC

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

MA08.03 EGFR-TKI Plus Brain Radiotherapy Versus EGFR-TKI Alone in the Management of EGFR Mutated NSCLC Patients With Brain Metastases: A Meta-Analysis

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Shikonin Sensitizes Wild‑type EGFR NSCLC Cells to Erlotinib and Gefitinib Therapy

Molecular Medicine Reports
OncologyGeneticsMolecular BiologyBiochemistryCancer ResearchMolecular Medicine
2018English

P3.01-16 Low Dose Apatinib Combined With EGFR-TKI in Treating Advanced NSCLC After First-Generation EGFR-TKIs Treatment Failure

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Cabozantinib Is More Effective Than Erlotinib in EGFR –Wild-Type NSCLC

Cancer Discovery
Oncology
2016English

Trastuzumab Emtansine Delays and Overcomes Resistance to the Third-Generation EGFR-TKI Osimertinib in NSCLC EGFR Mutated Cell Lines

Journal of Experimental and Clinical Cancer Research
Cancer ResearchOncology
2017English

The Effect of TKI Therapy and Chemotherapy Treatment Delivery Sequence on Total Progression‑free Survival in Patients With Advanced EGFR‑mutated NSCLC

Oncology Letters
Cancer ResearchOncology
2020English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy